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ABSTRACT 
So far the CÏ inactivator, a2-macroglobulin, antithrombin III (in the presence of heparin), 
and a,-antitrypsin have been identified as inhibitors of plasma kallikrein; a,-antitrypsin 
reacts slowly also with tissue kallikreins. Of the various naturally occurring kallikrein 
inhibitors the basic trypsin-kallikrein inhibitor of bovine organs, aprotinin (the active 
substance of Trasylol®), has attained by far the most interest. This inhibitor, which is 
produced by mast cells, has unusual properties due to its compact tertiary structure. 
Additional topics of aprotinin and structurally related inhibitors discussed are the mecha-
nism of enzyme-inhibitor complex formation, the production of chemical mutants of 
aprotinin, the structural basis of kallikrein inhibition, and selected aspects regarding apro-
tinin medication.—Fritz, H., E. Fink and E. Truscheit. Kallikrein inhibitors. Federation 
Proc. 38: 2753-2759, 1979. 
SPECIFIC AND NONSPECIFIC 
KININOGENASES 
A common feature of trypsin and 
trypsin-like enzymes with broader 
substrate specificity, e.g., plasmin and 
sperm acrosin, is the cleavage of 
arginyl- and lysyl-peptide bonds; 
that is, as nonspecific kininogenases 
they normally also liberate bradykinin 
from the kininogens, the natural 
substrates of the specific kinino-
genases or kallikreins. The kalli-
kreins are characterized, on the other 
hand, by their limited substrate 
specificity: Tissue kallikreins ( M r 
~ 25,000-35,000) from submandib-
ular glands, pancreas, urine (kidney), 
colon, etc. react preferably with low 
molecular weight kininogen yielding 
kallidin (13), whereas plasma kal-
likrein has two preferential biological 
substrates, high molecular kininogen 
and the Hageman factor (36). 
PLASMATIC INHIBITORS 
OF KALLIKREIN 
Both plasma kallikrein and high 
molecular weight kininogen are in-
volved in the solid phase activation 
of the intrinsic blood clotting cascade 
(36). The significance of simultaneous 
kinin liberation is not yet fully under-
stood. The relationship of plasma 
kallikrein to the clotting factors is 
outlined also by its inhibitory speci-
ficity (see Table 1): Plasma kallikrein 
exhibits highest affinity to the in-
activator of the CI esterases, but 
inhibition by a2-macroglobulin also 
occurs under in vivo conditions ( 1,22, 
36, 41). Antithrombin III reacts 
relatively slowly with plasma kal-
likrein; complex formation is ob-
served only when the concentration 
of the CI inactivator is low and 
heparin is administered simultane-
ously in therapeutical dosage (5, 31). 
Inhibition of plasma kallikrein by 
^-antitrypsin proceeds too slowly to 
be observed under in vivo condi-
tions (14). 
So far, of all plasmatic inhibitors 
only ^-antitrypsin has been un-
equivocally identified as an inhibitor 
of tissue kallikreins; it is a progressive, 
slowly reacting inhibitor (14). In 
addition, the presence of a fast react-
ing inhibitor of tissue kallikreins in 
human plasma has also been reported 
(13). Tissue kallikreins, to our present 
knowledge, act primarily as kinin-
generating enzymes. 
Inhibition by the plasmatic in-
hibitors is under in vivo conditions 
i r r e v e r s i b l e . In the case of a2-macro-
globulin the proteinases are en-
trapped after cleavage of a suitable 
peptide bond of the inhibitor (41); in 
this cage the enzyme is still accessible 
to lower molecular weight substrates 
and inhibitors but normally not to the 
natural higher molecular weight sub-
strates (41). The plasma kallikrein-
02-macroglobulin complex is one of the 
few exceptions; it still reacts with 
kininogens (36). In the form of the 
a2-niacroglobulin complex the pro-
teinase is rapidly eliminated from the 
circulation by cells of the reticulo-
endothelial system (2, 37). Irreversi-
ble inhibition of proteinases by the 
other plasmatic inhibitors occurs by 
formation of a covalent bond between 
the serine residue of the active site of 
the proteinase and an amino acid 
residue near the C-terminal region of 
the inhibitor after cleavage of a pro-
teinase-sensitive bond of the in-
hibitor (6, 21, 38). 
THE KALLIKREIN INHIBITOR 
FROM BOVINE ORGANS 
Inhibitors of plasma and/or tissue 
kallikreins are produced by various 
plants like potatoes and peanuts (15), 
by animal tissues like kidneys (20), 
and by bacteria such as the microbial 
peptides antipain and leupeptin (15). 
The inhibitor, however, that has 
attained by far the most interest of 
biochemists, pharmacologists, and 
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TABLE 1. Inhibitors of plasma kallikrein of physiological or medical relevance 
(preferentially inhibited enzymes in italics) 
In human plasma Inhibits plasma kallikrein and: (36) 
CÎ inactivator C l s , C I r , plasmin 
cr2-Microglobulin N e u t r a l and acidic proteases f r o m leukocytes a n d lysosomes," pancre-
atic proteases,0 bacterial and mold proteases; plasmin 
Antithrombin III -I- heparin T h r o m b i n , f a c t o r X a \ IXa, XIa, XI la , XIIa f r a g , V i l a ; CIs; plasmin 
o r Antitrypsin r N e u t r a l proteases f r o m leukocytes a n d lysosomes, pancreatic proteases,1* 
tissue kallikreins, plasmin 
Aprotinin from bovine lung Tissue k a l l i k r e i n s , p l a s m i n , trypsin, chymotrypsin 
" K las ta se. cathepsin G, collagenase, cathespin B and D, e.g. 6 Chymotrypsin, trypsin. ' Slowly 
reacting with plasma and tissue kallikreins or plasmin, therefore probably without physiological relevance 
regarding the in vivo inhibition of these proteases. 
is the main reason for the unusual 
stability of aprotinin against dena-
turation by high temperature, acid, 
alkali, organic solvents, or proteolytic 
degradation (30). The high dipole 
character of the aprotinin molecule 
is due to concentration of negatively 
charged residues near the bottom of 
the pear. 
Mechanism of complex formation 
The region of the inhibitor molecule 
that is in close contact with the enzyme 
in the trypsin-inhibitor complex is 
indicated by the hatched area at the 
physicians is the kallikrein inhibitor 
from bovine organs, aprotinin or 
Trasylol®, see Table 1. It was dis-
covered 50 years ago by Frey, Kraut 
and Werle as "kallikrein inactivator" 
in bovine lymph nodes and, 6 years 
later, independently by Kunitz and 
Northrop as trypsin inhibitor in 
bovine pancreas (13, 48, 49). 
Properties and structure 
The following properties of aprotinin 
are especially striking. 1 ) It forms 
equimolar and reversible complexes 
with trypsins, chymotrypsins, plas-
mins, and plasma as well as glandular 
kallikreins of various species (13, 48, 
49). 2) Its high stability is due to the 
low molecular weight of 6,500 daltons 
and an unusually rigid tertiary struc-
ture (7). 3 ) Its high basicity (the iso-
electric point is close to 10.5) is re-
sponsible for the marked affinity of 
this protein to negatively charged 
groups, causing adsorption of the 
inhibitor to mucoprotein layers (23) 
and fixation to the brush border 
membrane of the kidney after thera-
peutical administration (29). 4 ) It 
exhibits low toxicity and antigenicity 
(13,48,49). 
The structure of the aprotinin 
molecule is shown in Fig. 1 (7, 49): 58 
amino acid residues are aligned to a 
single polypeptide chain, which is 
cross-linked by three disulfide bridges. 
The polypeptide chain is folded in 
such a way that a pear-shaped mole-
cule results with the hydrophobic 
residues concentrated in the interior 
of the pear and the hydrophilic 
residues exposed to the surrounding 
medium. This arrangement leads to a 
very compact tertiary structure, which 
Figure 1. Tertiary structure of the aprotinin molecule as revealed by X-ray crystallographic 
studies (26). The polypeptide chain, consisting of 58 amino acid residues cross-linked by three 
disulfide bridges, is folded in such a way that a pear-shaped molecule results. The reactive peptide 
bond Lys 1 5 -Ala 1 6 is localized at the top of the pear. The region of the inhibitor molecule that is in 
close contact with the enzyme in the trypsin-inhibitor complex is indicated by the hatched area. 
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top of the pear (26): 12 residues of 
aprotinin, including its reactive site 
peptide bond Lys l 5 -Ala 1 6 , are in-
volved. All these contacts (11-13 
hydrogen bonds, a salt bridge, more 
than 200 Van der Waals interactions) 
contribute to the free energy of 19 
kcal/mol, the driving force of the 
complex formation, resulting in an 
extremely low dissociation constant, 
K i of 6 X 10"14 mol/liter (32). 
As schematically outlined in Fig. 2, 
formation of such a tight enzyme-
inhibitor complex is normally associ-
ated with i ) a perfect fit of the reac-
tive-site residue of the inhibitor into 
the specificity pocket of the enzyme; 
i t ) the formation of a tetrahedral 
intermediate by an attack of the 
nucleophilic hydroxyl group of the 
serine residue of the active site of the 
enzyme on the carbonyl group of the 
lysine residue of the reactive peptide 
bond of the inhibitor, and Hi) stabili-
zation of the adduct by additional 
weaker interactions in the vicinity 
of the specificity pocket and reactive 
peptide bond, respectively (26, 27, 
32). Taking into account the surplus 
of energy gained by the numerous 
contacts between enzyme and in-
hibitor, it is not surprising that not both, 
formation of the tetrahedral inter-
mediate and the perfect fit of the 
reactive site residue of the inhibitor 
(Lys in Fig. 1 and 2) into the speci-
ficity pocket of the enzyme are 
absolutely necessary for complex 
formation. In fact, the enzymatically 
inactive anhydro-trypsin forms also a 
tight complex with aprotinin (see 
Table 2) (25, 32). 
The energy gained by the contact 
of the complementary regions is even 
high enough to enable the aprotinin 
to push the conformation of trypsin-
ogen into the conformation of the 
active enzyme without the activation 
peptide being cleaved off (Table 2) 
(4, 46). On the other hand, the rela-
tively low affinity of aprotinin to 
chymotrypsin in comparison to tryp-
sin reflects primarily the disturbed 
fit of the Lys15-residue into the speci-
ficity pocket of this enzyme (3). 
In the case of the plasmin-aprotinin 
complex the contact regions of the 
partners should be distinctly smaller 
and/or their fit not nearly as perfect 
as in the trypsin-aprotinin complex 
(see Table 2). The same should hold 
true for the complexes formed between 
various kallikreins and aprotinin, as 
may be deduced from the K< values 
compiled in Table 3 (10, 17). In this 
respect it is interesting that, based on 
the primary structure of porcine 
pancreatic kallikrein as elucidated 
TABLE 2. Dissociation constants (Kt) 
of complexes between aprotinin and 
various partners 
Kn/.ymc/ 
partner Species Ki (mol/liter) pH 
Trypsin Bovine 6.0 X IO" 1 4 8 
Anhydro-
trypsin Bovine <3.0 X 10"1 3 8 
Tryp-
sinogen Bovine 1.8 X 10"8 8 
Chymo-
trypsin Bovine 9.0 X 10"9 8 
6.0 X 10"9 7 
Plasmin Porcine 4.0 X 10"9 8 
Human 2.3 X 10"1 0 8 
recently (45), 57% of the amino acid 
residues of trypsin mediating the 
contact in the complex with aprotinin 
are preserved in kallikrein; especially 
the residues participating in more 
than just one interaction with the 
inhibitor remain unchanged. Of the 
numerous interactions in the trypsin-
aprotinin complex about 70% also 
seem to be possible in the complex 
with porcine pancreatic kallikrein, 
especially the contacts around the 
reactive site peptide bond Lys 1 5-
Ala 1 6 of the inhibitor (45). 
Structurally homologous 
inhibitors—structural basis 
of kallikrein inhibition 
Another possible approach for ob-
taining an insight into the structural 
basis of kallikrein inhibition by apro-
tinin is a comparison of the inhibition 
specificities and reactive site se-
quences of structurally homologous 
inhibitors (Table 4) (10, 24). From the 
results of the crystallographic work 
it is known that the amino acid resi-
dues of aprotinin with the most 
intimate contact to trypsin in the 
complex are, besides Cys 1 5 and Cys 3 8, 
TABLE 3. Dissociation constants of 
complexes between aprotinin and 
various kallikreins 
K i 
Kallikrein Species (mol/liter) pH 
Pancreatic Porcine 1 X 10"9 8.0 
Subman-
dibular Porcine 1.6 X 10"9 9.0 
Urinary Porcine 1.7 X 10"9 9.0 
Human 1 X 10" 1 0 8.0 
Plasma Human 3 X 10"8 8.0 
Porcine 1 X 10"7 7.8 
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T A B L E 4. Identified a n d mutual reactive site res idues of structurally related t r y p s i n - c h y m o t r y p s i n inhibitors of the aprot in in type 
Inhibition of 
Positions of" the residues Tissue Plasma 
Inhibitor (from) P2 P, P,' P2' P/ P.-,' P» Plasmin 
kalli-
kreins 
kalli-
kreins 
(Position") 14 15 16 17 18 19 20 38 39 
Aprotinin Cys Lys- Ala Arg He He Arg Cys Arg + + + + + 
SAI, sea anemone Cys Arg- Ala Arg Phe Pro Arg Cys Arg + + + + + 
HPI K , snail Cys Lys- Ala Ser Phe Arg Gin Cys Arg + + + + 
R V V II, snake venom Cys Arg-Gly His Leu Arg Arg Cys Gly + + + 
N N V II, snake venom Cys Lys- Ala Arg lie Arg Ser Cys Gly + + + 
H H V II, snake venom Cys Lys- Ala Tyr He Arg Ser Cys Gly + + + + + 
CTI, cow colostrum Cys Lys- Ala Ala Leu Leu Arg Cys Gin + + - -
Kunitz, soybean* Tyr Arg-He Arg Phe Ile Ala + + - + + 
" In aprotinin. h Structurally not homologous. + + strong, + weaker, — no inhibition; <f> not tested. 
the "specificity pocket" residue Lys 1 5, 
Ala 1 6 and the basic residues Arg 1 7 and 
A r g 3 9 (26). Regarding the inhibition 
specificities of the structurally homol-
ogous inhibitors, it is evident that the 
basic nature of the residues in posi-
tions 17 and 39 is in favor of the 
relatively strong interaction of apro-
tinin with the kallikreins. Exchange 
of both amino acid residues in these 
positions by neutral residues (see 
the cow colostrum inhibitor) com-
pletely abolishes the affinity of apro-
tinin-type inhibitors to both tissue 
and plasma kallikreins. 
If, on the other hand, a basic resi-
due is present in position 19 (see 
snake venom inhibitor H H V II), 
kallikrein inhibitory activity is ex-
hibited again. Obviously, in an apro-
tinin-type inhibitor the basic nature 
of amino acid residues in one or more 
of the positions 17, 19, and 39 is 
necessary to gain enough energy for 
complex formation with a kallikrein. 
In contrast, the affinity of an 
aprotinin-type inhibitor to plasmin 
Bovine lung T K I 0.8 
Sea anemone SAI 5-II 0.8 
Snake venom NNV-II 1.1 
Snake venom HHV-I I 8.3 
Snail H P I K 27.7 
Cow colostrum C T I — 
Values in nanomoles per liter. - , no inhibition. 
and trypsin is not significantly af-
fected by such amino acid exchanges 
in the reactive site region. It may be 
concluded, therefore, that inhibition 
of plasma and particularly of glandu-
lar kallikreins presupposes additional 
structural requirements in specific 
subsite positions of a trypsin or 
plasmin inhibitor, thus reflecting the 
more restricted substrate specificity 
of the kallikreins compared to trypsin 
or plasmin. On the other hand, the 
conclusion is then justified that the 
active site regions of all kallikreins 
that form a complex with aprotinin 
are very similar, especially if the K{ 
values of the complexes are so closely 
related, as in the case of porcine tissue 
kallikreins (Table 5) (10). 
The reactive site bond— 
chemical mutants of aprotinin 
There is general agreement that 
aprotinin is a single-headed inhibitor 
with the Lys15-residue in its active 
center. Location of the reactive site 
0.9 1.0 
0.6 0.8 
1.3 1.3 
210 109 
210 204 
peptide bond within the sequence of 
an inhibitor is normally proved by 
limited proteolysis in slightly acidic 
solution, resulting in the formation of 
an equilibrium between virgin and 
modified (with the reactive site bond 
hydrolyzed) inhibitor and resynthe-
sis of the virgin inhibitor from the 
modified one under suitable condi-
tions (12), see Fig. 3 (upper part). Due 
to the high stability of the virgin 
inhibitor molecule these reactions 
proved to be especially difficult to 
achieve in the case of aprotinin 
(43, 44). 
The modified inhibitor was used to 
produce chemical mutants of apro-
tinin (28, 43). As expected, replace-
ment of Lys 1 5 by Arg via several steps 
(cf. left and lower part of Fig. 3) did 
not influence the inhibitory proper-
ties of aprotinin, whereas replace-
ment of the basic active site residue 
by Phe or Trp caused a significant 
increase in the affinity of the inhibi-
tory protein for chymotrypsin and 
decrease in the affinity for trypsin. 
The total synthesis of aprotinin 
achieved recently opens a way to study 
the influence of amino acid exchanges 
on the inhibitory properties of this 
molecule in detail (42). 
Selected aspects of 
aprotinin medication 
In view of the application of aprotinin 
(e.g., as Trasylol, the registered trade 
name in favor of Bayer A G , Germany) 
in medical therapy and experimental 
animal studies, some of its properties 
are of special interest. 
T A B L E 5. D issoc ia t ion constants Kt of c o m p l e x e s between aprot inin-type inhibitors (cf. 
Tab le 4) a n d p o r c i n e t issue kall ikreins 
Kallikrein from porcine 
Structurally homologous 
inhibitor from Pancreas Submand. gland Urine 
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Virgin inhibitor 
14 ß KS 38 
-Cys - Lys - Ala Cys L y   
T 
plasmin, pH 5 
(l)reduction (2)enzymic 
(3)CpdaseB modif. 
•Cys 
L 
Ala-
s-s-
•Cys-
(4) Arg, Cpdose B, 
trypsin complex ^ 
(5) Phe or Trp, CpdaseA, 
chymotr. complex 
Modified inhibitor 
Çys-Lys Ala Cys-
S-S 
(5) Phe or Trp 
(4) 
-Cys-Arg-Ala Cys-
-s-s 
Des- Lys inhibitor Semisynthetic inhibitor 
Figure 3. Modification of aprotinin by limited proteolysis. By the action of catalytic amounts of 
plasmin at pH 5 a thermodynamic equilibrium is accomplished between virgin inhibitor (reactive 
site peptide bond intact) and modified inhibitor (reactive site bond hydrolyzed), cf. upper part. 
Semisynthetic reactive site modified inhibitors are obtained by a series of chemical and enzymic 
reactions as indicated in the left and lower part of the figure: / ) selective reduction of the Cys 1 4-
Cys 3 8 disulfide bridge, 2 ) selective proteolytic cleavage of the Lys , 5 -Ala 1 6 peptide bond, 3 ) removal 
of Lys 1 5 by treatment with carboxypeptidase B, 4 ) insertion of Arg and resynthesis of the reactive 
site peptide bond via the trypsin complex, 5 ) insertion of Phe or Trp and resynthesis of the reactive 
site peptide bond via chymotrypsin complex. 
Aprotinin strongly inhibits both 
human cationic and anionic trypsin 
but rather weakly inhibits human 
chymotrypsin I and human pancre-
atic protease E or elastase; human 
chymotrypsin II is not inhibited (11, 
34, 35). Tissue kallikreins and plasma 
kallikrein of man, pig, arid cattle are 
relatively strongly inhibited by apro-
tinin, whereas the corresponding 
kallikreins of guinea pig and dog are 
not inhibited (47, 48). We emphasize 
especially the rather strong inhibition of 
human plasmin and human tissue 
(urinary, submandibular, pancreatic) 
kallikrein—Kj values close to 0.1 
nmol/liter were reported for the 
corresponding complexes, cf. Tables 
2 and 3—compared to the clearly 
weaker inhibition of human plasma 
kallikrein—the K f value of this complex 
is higher than 10 nmol/liter, cf. Table 
3. Due to this significant difference 
in the affinity of aprotinin to plasmin 
and plasma kallikrein it seems possi-
ble to regulate the desired effect, 
namely inhibition of plasmin and thus 
fibrinolysis or of plasma kallikrein 
and hence blood clotting, by the 
amount of inhibitor administered 
(16, 39). Regarding the release of 
appreciable amounts of neutral leu-
kocytic proteinases during the inflam-
matory response, inhibition of gran-
ulocytic elastase by aprotinin is also 
of interest (33). 
The trypsin-like acrosomal pro-
teinase acrosin, which assists the 
spermatozoa to penetrate the zona 
pellucida of the ovum, is also, though 
rather weakly, inhibited by aprotinin 
(18). In vivo application of aprotinin 
for contraceptive purposes is hin-
dered further by the high concentra-
tion (about 10 mmol/liter) necessary 
to achieve passage of the inhibitor 
across sperm head membranes (W.-B. 
Schill, G. Feifel and H . Fritz, ms in 
preparation). Implantation of blasto-
cysts into rabbit uteri could be pre-
vented, however, in the presence of 
much lower concentrations (about 1 
/xmol/liter) of aprotinin probably via 
inhibition of a trypsin- or kallikrein-
like trophoblast proteinase (8, 9). 
Occurrence in bovine tissue and 
possible biological function 
Although detailed knowledge of the 
biochemistry, pharmacology, and 
mechanism of action of aprotinin has 
accumulated, its physiological func-
tion in the bovine organism has so far 
remained obscure (13, 48, 49). This 
was due, at least partly, to its wide-
spread distribution in functionally 
totally different organs such as lung, 
Figure 4. Localization of aprotinin in mast cells as revealed by immunofluorescence (19). a) Distribution pattern of the fluorescent spots in tis-
sue sections of bovine lung after treatment with aprotinin-specific antibodies (control sections treated with unspecific antibodies showed no 
fluorescence), b) Distribution pattern of the mast cells as revealed by metachromatic staining with toluidine blue. Magnification: x 128. 
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parotid gland, lymph nodes, liver, 
pancreas, seminal vesicles, ovary, 
heart, etc. The availability of aproti-
nin antibodies stimulated us to look 
for the origin of this inhibitor at the 
cellular level, hoping to find in this 
way an indication of its biological 
function. Figure 4b shows the dis-
tribution of mast cells in tissue sec-
tions of bovine lung as revealed by 
selective staining with toluidine blue. 
The similar pattern of fluorescent 
spots obtained after treatment of 
acetone-fixed tissue sections with 
aprotinin-directed antibodies using 
the indirect immunofluorescence tech-
nique (Fig. 4a) indicates strongly 
that aprotinin is localized in mast cells 
(19). In order to corroborate the mast 
cell character of the cells showing 
specific fluorescence, additional com-
bined light and electron microscopic 
studies were performed (19). The 
granulated cells thus identified were 
identical with the cells showing 
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